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SUMMARY
The transcription factor Krüppel-like factor 4 (KLF4) is an important regulator of cell fate
decision, including cell cycle regulation, apoptosis, and stem cell renewal, and plays an
ambivalent role in tumorigenesis as a tissue specific tumor suppressor or oncogene. Here we
report that the Von Hippel-Lindau gene product, pVHL, physically interacts with KLF4 and
regulates its rapid turnover observed in both differentiated and stem cells. We provide mechanistic
insights into KLF4 degradation and show that pVHL depletion in colorectal cancer cells leads to
cell cycle arrest concomitant with increased transcription of the KLF4-dependent p21 gene.
Finally, immunohistochemical staining revealed elevated pVHL and reduced KLF4 levels in colon
cancer tissues. We therefore propose that unexpectedly pVHL, via the degradation of KLF4, is a
facilitating factor in colorectal tumorigenesis.
INTRODUCTION
The ubiquitin-proteasome system plays an important role in controlling the level, activity
and location of various cellular proteins. Particularly, many transcription factors are unstable
proteins and their rate of destruction is regulated by specific E3 ligases. Examples of
proteolytic regulation of transcription factors involved in carcinogenesis include the
targeting of tumor suppressor p53 by MDM2 and the oncoprotein Myc by Skp2. Another
well documented example is the degradation of hypoxia inducible factor (HIF) by the von
Hippel-Lindau (pVHL) tumor suppressor (Kaelin, 2007).
Krüppel-like factor 4 (KLF4, GKLF) is a transcription factor involved in cellular responses
to a variety of environmental and intracellular stress signals such as DNA damage, oxidative
stress, and inflammation (Evans and Liu, 2008). KLF4 activation determines the cell fate by
activating or inhibiting a network of genes involved in cellular functions as diverse as cell
cycle regulation, stem cell renewal, adhesion, apoptosis, or metabolism (Rowland and
Peeper, 2006). Several of these KLF4 regulated pathways affect checkpoints in cancer
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development. Surprisingly, KLF4 appears to function as an oncogene or tumor suppressor
depending on the tissue type. Although several KLF4 downstream-targets have been well
characterized, it is unknown why elevated KLF4 levels promote tumorigenesis in the skin,
but inhibit cancer formation in the colon. Indeed, the mechanisms of KLF4 activation itself
are largely unexplored. The expression of KLF4 is strongly induced after genotoxic stress,
such as γ–irradiation (Ghaleb et al., 2007), and serum starvation (Chen et al., 2005).
Following the observation that KLF4 is a protein with a high turnover rate, we attempted to
identify proteins that regulate it post-translationally and here report the interaction of KLF4
with pVHL.
Mutations in the VHL gene have been linked to a variety of tumors including clear cell renal
carcinoma, retinal and cerebellar hemangioblastoma, and phaeochromocytoma (Kaelin,
2007). The VHL protein is the substrate-recognizing subunit of the CBCVHL E3 ubiquitin
ligase complex consisting of pVHL, the elongins B and C, Cullin 2, and the RING-H2 finger
protein Rbx1. CBCVHL binds and degrades the α subunits of the heterodimeric hypoxia-
inducible transcription factors HIF1 and HIF2 (Maxwell et al., 1999). Recognition of HIF1
and HIF2 by pVHL is contingent on the post-translational modification of conserved HIF
proline residues located within LXXLAP motifs by specific prolyl-hydroxylases (PHDs), a
process involving molecular oxygen (reviewed in (Kaelin, 2008)). Under normoxic or
athmospheric oxygen levels, HIF α subunits are efficiently modified by PHDs, ubiquitylated
by CBCVHL, and rapidly degraded by the 26S proteasome. However, under hypoxic
conditions proline hydroxylation is inhibited and HIF-α subunits are stabilized, leading to
their dimerization with constitutively stable HIF-β subunits and activation of hypoxia-
responsive genes. Absence or dysfunctional pVHL leads to impaired downregulation of HIF
under normoxic conditions and constitutive expression of HIF target genes, likely a key
pathogenic event in VHL disease as evidenced by xenograft assays and immunostaining of
patient tissues (Kaelin, 2008). However, increasing evidence indicate that pVHL activity is
not limited to regulation of HIFs. Other substrates of its ubiquitin ligase activity include
atypicial protein kinase Cλ, pVHL-interacting deubiquitinating enzymes VDU1 and VDU2,
and two subunits of RNA polymerase II (Rpb1 and Rpb7). Unrelated to its ligase activity,
pVHL was shown to bind and stabilize p53 and Jade-1, to regulate microtubule stability,
assembly of extracellular matrix and intercellular junctions, and primary cilium maintenance
(Nyhan et al., 2008), and to promote proper spindle orientation and chromosomal stability
(Thoma et al., 2009). In addition, pVHL was found to play a HIF-independent role in cell
cycle regulation. Vhl−/− mouse embryonic fibroblasts (MEFs) and fibrosarcomas derived
thereof grow slower than the corresponding Vhl+/+ cells (Mack et al., 2005) and acute loss
of Vhl triggered a senescence-like growth arrest in MEFs that was independent of p53 and
HIF (Young et al., 2008). Furthermore, p21 and p27 levels are elevated in embryonic stem
cells and MEFs derived from Vhl−/− mice (Mack et al., 2005) and inactivation of the Vhl
locus in MEFs leads to an increase in p27 levels (Young et al., 2008). Intriguingly, both
cyclin-dependent kinase inhibitors, p21 and p27, are reported downstream targets of KLF4
(Rowland and Peeper, 2006; Wei et al., 2008).
In this study, we report that pVHL interacts directly with and degrades KLF4 via the
ubiquitin-proteasome pathway. Furthermore, VHL deficiency in colon cancer cells leads to
KLF4 upregulation and concomitant increase of p21 transcription as well as to cell cycle
arrest. Our findings suggest that KLF4 is a downstream mediator of HIF-independent roles
of VHL. As such KLF4 provides a new link in the pathway leading to growth arrest
triggered by the loss of VHL observed in certain cells. In such cells, characterized by a
requirement of KLF4 for proliferative control, pVHL overexpression could contribute to
tumor formation, at least at the early stage of tumorigenesis. Indeed, we find that pVHL
upregulation associated with a decrease in KLF4 levels is a common feature in colon
cancers. Mechanistically, we identified the KLF4 amino-terminus as particularly important
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for the regulation of KLF4 turnover by being the site of ubiquitylation and pVHL binding.
Our findings provide the basis for future studies on how KLF4 degradation is regulated and
how VHL affects KLF4 functions in other pathways such as stem cell renewal and
apoptosis.
RESULTS
The transcription factor Krüppel-like Factor 4 (KLF4) plays an ambivalent role in
tumorigenesis. It can act both as a tissue specific tumor suppressor or oncogene, likely due
to its ability to induce cell cycle arrest and/or block apoptosis. Recently, KLF4 has also
drawn a lot of attention due to its role as key factor in stem cell renewal and induction of
pluripotency in differentiated cells. In all cases, tight regulation of KLF4 levels is pivotal for
cell fate decisions. Indeed, expression of KLF4 is strongly induced after genotoxic stress,
such as γ–irradiation (Ghaleb et al., 2007), and serum starvation (Chen et al., 2005). Because
KLF4 was previously reported to be highly unstable in HCT116 (Chen et al., 2005), we
tested whether the same was true for HeLa cells. Under homeostatic conditions KLF4 has a
high turnover rate in HeLa cells as shown by an immunoblot after inhibiting protein
synthesis (Fig. 1A). HeLa S cells were treated with cycloheximide for 0, 2, 4, 6, and 8 hours
and KLF4 levels were assessed by immunoblots for KLF4. KLF4 was rapidly degraded with
a half-life of around 4 hours, suggesting that post-translational regulation plays an important
part in determining cellular KLF4 levels.
pVHL co-precipitates with KLF4
To identify proteins that might regulate KLF4 degradation we established HeLa cell lines
stably expressing FLAG-tagged KLF4. Cytosolic and nuclear extracts were prepared from
HeLa cells and HeLa cells expressing tagged KLF4. Both, tagged and endogenous KLF4
showed similar degradation kinetics and cellular distribution (data not shown), with the
majority found in the nuclear fraction in agreement with previous findings (McConnell et
al., 2007). Tagged KLF4 and interacting partners were precipitated with M2-(anti-FLAG)-
agarose from nuclear extracts and analyzed by SDS-PAGE and Coomassie blue staining.
HeLa cells served as control (Fig. 1B). Prominent bands were excised and sent for mass
spectrometric sequencing leading to the identification of several proteins with a potential
role as transcription cofactors (data not shown). The smear above 100 KDa was mainly due
to post-translationally modified KLF4. The immunoprecipitate was also subjected to
immunoblotting with a collection of antibodies against E3 ligases or subunits of ubiquitin-
ligase complexes. Fig. 1C shows that, unlike several other tested E3 ligases, the van Hippel-
Lindau gene product pVHL was specifically precipitated by tagged KLF4. pVHL is the
substrate recognizing subunit of a multiprotein ubiquitin-ligase complex that also contains
Cullin2, the Elongins B and C, and Rbx1. We tested for Cullin2 and Elongin B and found
that they also co-precipitated with KLF4, although it seems with lower efficiency than
pVHL, probably because not all KLF4-bound pVHL is complexed and/or Cullin2 and
Elongin B also associate with other proteins to form complexes. This suggests that the
observed binding of pVHL with KLF4 is direct. VHL has two isoforms migrating as
approximately 28 and 18 kDa proteins and of roughly equal cellular abundance.
Interestingly, only the long form of pVHL binds KLF4 (Suppl. Fig. S1A), indicating that the
pVHL fragment lacking in the 18 kDa form is directly binding KLF4 or important for the
required pVHL folding. Endogenous pVHL also co-precipitated with endogenous KLF4
from the nuclear extract of HCT116 cells (Suppl. Fig. S1B).
KLF4 directly interacts with pVHL
To test whether KLF4 and pVHL interact directly, GST and GST-fused full-length pVHL
proteins (Suppl. Fig. S1C) were independently bound to glutathione-Sepharose and
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incubated with in vitro translated KLF4. KLF4 bound to pVHL, but not to the control GST
(Fig. 1D). In a similar assay, also His-tagged KLF4 purified from bacteria bound GST-
pVHL, but not GST (Suppl. Fig. S1E). Furthermore, we tested intracellular interactions by
transient co-expression of FLAG-HA-tagged KLF4 with untagged pVHL in MDAMB231
cells. Derived whole cell lysates were incubated with M2 (anti-FLAG) agarose and
immunoprecipitates were analyzed by immunoblot. pVHL was co-immunoprecipitated with
KLF4, albeit more efficiently when KLF4 expressing cells were treated with the ubiquitin-
proteasome inhibitor MG132 before harvesting (Fig. 1E). The interaction of pVHL with
KLF4 is therefore direct and not specific to HeLa.
KLF4 is post-translationally regulated by VHL
To test whether pVHL controls KLF4 turnover, we wanted to look at VHL-negative cells.
Because VHL loss is embryonic lethal and because we did not want to use cancer cells (such
as VHL-negative clear cell carcinomas), we resorted to embryonic stem cells (ESCs) derived
from mice lacking Vhl described earlier (Rathmell et al., 2004). Interestingly, these cells
have elevated levels of the cdk inhibitors p21 and p27 (Mack et al., 2005) compared to wild
type or Vhl hemizygous mice. We examined KLF4 protein levels in ESCs from Vhl+/− and
Vhl−/− mice as well as in Vhl−/− ESCs reconstituted with human wild type (VHLwt) or
mutant VHL (VHL112H) cDNA (Rathmell et al., 2004). Immunoblots using two different
antibodies against KLF4 show highly elevated levels of KLF4 in Vhl−/− compared to Vhl+/−
ESCs (Fig. 2A, compare lanes 1 and 2). Murine ESCs expressing human wild type or
Y112H mutant pVHL had KLF4 levels similar to Vhl+/− ESCs (Fig. 2A), indicating that
murine KLF4 is a downstream target of both murine and human pVHL. Furthermore,
deletion but not Y112H mutation of VHL leads to KLF4 upregulation. Tyrosine 112 lies in
the beta domain of VHL (Stebbins et al., 1999), in the pocket bound by the carboxy-terminal
oxygen-dependent degradation motif of HIF1α (Hon et al., 2002). Y112H is a frequent
mutation found in VHL patients and was proposed to impair the ability of pVHL to bind and
degrade human HIF1α. The fact that Y112H mutant pVHL was able to lower KLF4 levels
suggests that VHL-dependent regulation of KLF4 is HIF-independent and/or
mechanistically different from the regulation of HIF by pVHL.
Vhl+/−, Vhl−/− and VHLwt ESCs have similar KLF4 mRNA levels (Fig. 2B), suggesting that
KLF4 levels were not altered due to increased transcription or differences in RNA stability.
To further corroborate that KLF4 levels are post-translationally regulated, the stability of the
KLF4 protein was tested by measuring protein levels after blocking protein synthesis with
cycloheximide (CHX). KLF4 was rapidly degraded in VHLwt ESCs, but had a much longer
half-life in ESCs lacking VHL (Fig. 2C). To test whether VHL-mediated regulation of KLF4
is also a feature of human and differentiated cells, we used lentiviruses expressing shRNA to
knockdown VHL in HCT116 cells. A VHL-specific, but not control (empty) shRNA vector,
led to an approximately 75% reduction in VHL levels (Fig. 2E; see also Suppl. fig. S2 and
Experimental Procedures) and a strong induction of KLF4 levels (Fig. 2D). These findings
suggest that VHL-dependent regulation of KLF4 is a common feature of murine and human,
stem and differentiated cells.
KLF4 has a short half-life in various cancer cells
KLF4 has been proposed to function as an oncogene or tumor suppressor depending on the
tissue type. Thus, KLF4 levels promote tumorigenesis in the skin, but inhibit cancer
formation in the stomach and colon. Furthermore, KLF4 over-expression represents a
common feature of breast cancers and probably constitutes an early event in their
development (Evans and Liu, 2008). We compared KLF4 levels in cancer cell lines derived
from colon (HCT116), lung (U2OS), and breast (HCC1937, MCF7, MDAMB231). KLF4
levels varied greatly with MDAMB231 having high and U2OS low levels of KLF4 (Suppl.
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Fig. 3A). Yet, treatment of HCT116 and MDAMB231 with cycloheximide showed that
turnover rates of KLF4 were rapid also in these cells with relatively high protein levels
(Figures 3A and 3B). Conversely, KLF4 levels increased drastically after treatment with
MG132, a proteasome inhibitor (Figures 3A and 3B, compare first and last lanes).
Furthermore, levels of exogenously expressed tagged KLF4 also rapidly declined in
transfected MDAMB231, U2OS, and HCT116, and MCF7 cells after addition of
cycloheximide (Figures 3C and 3D; data not shown). These results suggest that KLF4 is
kept at cellular steady state levels by a balance of synthesis and ubiquitin/proteasome-
mediated turnover in all tested cells, albeit at cell specific levels.
An amino-terminal region of KLF4 is required for its degradation
KLF4 functions as a gene specific activator or repressor. The approximately 55 kDa protein
contains an amino-terminal activation domain, shown to interact with the histone
acetyltransferases p300 and CBP, a central repressive domain and a carboxy-terminal DNA-
binding domain consisting of three zinc fingers. Two carboxy-terminal nuclear localization
signals target KLF4 to the nucleus (Evans and Liu, 2008). To identify the regions of KLF4
responsible for its degradation, we generated several FLAG-HA-tagged deletion mutants
(Fig. 4A). All deletion mutants retain the nuclear localization signal, avoiding artefacts due
to a potential difference in cellular localization. Deletion of the amino-terminal 108 amino
acids led to increased stability of KLF4 following cycloheximide treatment (Fig. 4B),
suggesting that the amino-terminus contained the ubiquitylation sites and/or the sites of
interaction with the ubiquitin ligase. Using additional deletion mutants, a region regulating
the degradation of KLF4 could be narrowed to the amino-terminal 50 residues, since
KLF4(41–470) was rapidly degraded, but KLF4(51–470) was stable (Fig. 4C). Interestingly,
the amino-terminus of KLF4 contains two lysines, K23 and K43, that could function as
acceptor sites for ubiquitin (Suppl. fig. S4C).
To determine regions of KLF4 necessary for pVHL binding, in vitro translated deletion-
mutants of KLF4 were incubated with glutathione-Sepharose bound GST-pVHL. An
analysis of bound proteins showed that amino acids 31–108 of KLF4 were essential for
pVHL binding since deletion of the amino-terminal 30 KLF4 residues did not affect binding
to GST-pVHL, whereas deletion of residues 1–108 abolished it (Fig. 4D). These findings are
in agreement with the previously determined region responsible for KLF4 turnover and
provide strong evidence for KLF4 being a direct substrate of the ubiquitin ligase pVHL. We
further dissected the interaction site of KLF4 with pVHL to see whether the stabilization of
KLF4 by the deletion of residues 41–50 is due to a disruption of pVHL binding to KLF4.
Deletion of up to 60 amino-terminal KLF4 residues though had no affect on its interaction
with pVHL (Fig. 4E, compare lanes 2 to 5), indicating that pVHL binding is mediated by
amino acids 61–108 of KLF4 and raising the possibility that residues 41–50 contain an
important ubiquitin acceptor site.
KLF4 degradation is mediated by VHL
To further test the relevance of KLF4 interaction with pVHL for KLF4 stability, we co-
expressed FLAG-HA-tagged KLF4 with increasing amounts of FLAG-HA-tagged pVHL in
U2OS cells. An immunoblot of the cell lysates showed that KLF4 was degraded by pVHL in
a dose-dependent manner (Fig. 5A). Importantly, deletion of amino-terminal 108 residues,
shown to be important for the interaction with pVHL (Fig. 4D) and to lead to stabilization of
KLF4 after cycloheximide treatment (Fig. 4C), also led to the inability of pVHL to target
KLF4 for destruction (Fig. 5B). These results support the hypothesis that pVHL interaction
with KLF4 is important for KLF4 degradation and, in combination with the data showing
increased endogenous KLF4 levels after VHL deletion or reduction, strongly suggest that
pVHL is a major regulator of KLF4.
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pVHL mediated degradation of its substrates is mediated by the ubiquitin-proteasome
pathway. We immunoprecipitated endogenous KLF4 with an antibody against KLF4 and
probed the immunoblot for ubiquitin. KLF4 showed a poly-ubiquitylation pattern
characteristic for proteins targeted for proteasome dependent degradation (Fig. 5C).
Treatment of cells with the proteasome inhibitor MG132 increased high molecular weight
ubiquitin signals (Fig. C, lanes 3 and 4).
The mechanistic role of the KLF4 amino-terminus in regulation by pVHL
Our studies with KLF4 deletion mutants indicate that the KLF4 amino-terminus plays a
special role in the regulation of KLF4: it contains the pVHL-interaction site (Fig. 4D) and
deletion of amino acids 40 to 50 stabilizes the protein (Fig. 4C). HIF1α and HIF2α contain
prolines within LAP (leucine-alanine-proline) consensus sequences that are hydroxylated by
prolyl-hydroxylases and subsequently bound by pVHL (Ivan et al., 2001; Kaelin, 2008).
Intriguingly, the KLF4 amino-terminus contains a proline at residue 81 in a region that also
would fit the description of the HIF degron (see Suppl. Fig. S4A). Mutation of proline 81 to
alanine though did not abolish pVHL-mediated degradation of KLF4 (Suppl. Fig. S4B),
suggesting that the mechanism of KLF4 degradation by pVHL differs from HIF destruction.
Interestingly, the amino-terminus of KLF4 contains two lysines, K23 and K43, within the
KLF4 activation domain. We next wanted to test whether these could function as acceptor
sites for ubiquitin. A previous proteomic screen for ubiquitylated proteins had identified
KLF4 K23 as an ubiquitylation site (Tan et al., 2008). We therefore introduced a charge
conserving K23R mutation in our tagged KLF4 vector and transfected HCT116 cells with a
plasmid expressing FLAG-HA-tagged wild type or mutant KLF4. The cells were treated
with MG132 before harvesting and precipitation of KLF4 from whole cell lysates with M2-
(anti-FLAG)-agarose. Ubiquitylation was analyzed by immunoblotting. A characteristic
smear for ubiquitylated KLF4 above 100 KDa was observed in precipitates of cells
expressing tagged wild type KLF4 (Fig. 5D, compare lanes 2 to 5). An immunoblot for
ubiquitin of purified mutant KLF4 revealed no significant change in ubiquitylation of the
K23R mutant compared to wild type (Fig. 5D, lanes 2 versus 3). Mutation of lysine K43
alone or in combination with K23R though nearly completely abolished KLF4
ubiquitylation (Fig. 5D, lane 4 and 5) indicating that K43 is a major receptor residue for
ubiquitin and likely the cause for the stabilizing effect of residues 40 to 50 deletion. To
further corroborate the importance of K43 for KLF4 ubiquitylation, we used the same
approach to examine the effect of deletion mutants in the amino-terminus on KLF4
ubiquitylation. Deletion of residues 1–30 did not significantly influence the degree of KLF4
ubiquitylation, whereas the deletion of an additional 20 residues (to KLF4 51–470)
drastically reduced the signal for precipitated ubiquitin chains (Fig. 5E), establishing K43 as
the main KLF4 acceptor site for poly-ubiquitin chains. Intriguingly, mutation of the amino-
terminal KLF4 lysines K23 and K43 protects KLF4 from pVHL mediated degradation (Fig.
5B).
Antimitotic affect of VHL knockdown in HCT116 cells
Previous reports have associated elevated KLF4 levels in HCT116 cells with growth arrest
(Yoon et al., 2003), likely due to the ability of KLF4 to induce the cdk inhibitor p21 and to
inhibit the cyclin D1 promoters (Evans and Liu, 2008). We therefore compared HCT116
cells with normal or pVHL levels reduced by stable shRNA mediated knockdown (see
Figures 2D and E). To investigate the impact of VHL status and the concomitant change in
KLF4 levels on the CDK inhibitor p21 transcription, we quantified p21 mRNA levels by
real time PCR. p21 mRNA levels were more than three times higher in VHL knockdown
HCT116 cells compared to wild type HCT116 (Fig. 6A), in agreement with higher p21
levels found in VHL-knockout murine embryonic stem cells (Mack et al., 2005).
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Measuring cell proliferation using an MTS assay, we found that HCT116 with wild type
VHL levels have a doubling time of less than 1 day in the exponential proliferation phase.
HCT116 cells with knockdown levels of VHL showed a much reduced proliferation rate
with doubling times of more than 48 hours, and sparsely seeded cells were particularly
growth impaired (Fig. 6B). Finally, to confirm that the observed colorimetric values of
formazan production in the MTS assay reflected VHL induced changes in cell cycle, we also
measured bromodeoxyuridine (BrdU) incorporation by immunocytochemical staining and
FACS. HCT116 with VHL knockdown have a strongly reduced population staining for
BrdU compared to wild type cells (Fig. 6C, 6D), mirroring the observed respective
proliferation rates.
In order to see whether the antimitotic effect of VHL knockdown is KLF4 dependent we
silenced KLF4 in VHL knockdown cells by transient transfection with siRNA against KLF4.
KLF4 silencing decreased p21 levels (Fig. 6F) and enabled VHL knockdown cells to reenter
the cell cycle as evidenced by increased BrdU staining (Fig.6E).
Increased levels of pVHL in colon cancer cells correlate with reduced KLF4 levels
pVHL is a well documented tumor suppressor and the loss of VHL plays an important role
particular in the formation of renal cancers (Kaelin, 2007). Our observations as well as
previous findings that VHL deficiency in mouse models impairs tumor growth (Mack et al.,
2005) and acute loss of VHL can lead to senescence (Young et al., 2008) allows for the
possibility that under certain conditions pVHL could function as tumor facilitating factor.
Such circumstances could be found in cells where KLF4 plays a role as tumor suppressor,
such as gastric and colorectal cells. Indeed, our analysis of a published Affymetrix
microarray data set from 5 normal and 100 cancer colon tissues (Kaiser et al., 2007),
revealed that none of the assayed colon cancer cells showed loss of the VHL gene or even
reduced VHL transcription. Indeed, VHL mRNA levels in the colon cancer cells were
significantly upregulated, although on average by a small percentage (Fig. 7A). Because
RNA levels often are a poor indicator for actual protein expression, we used histochemical
staining to look at the expression of both pVHL and KLF4 in colon cancer and adjacent
tissue samples. As expected given the well documented role of KLF4 as tumor suppressor in
colorectal and gastric cancers, KLF4 levels were significantly decreased in colon cancer
tissues. Intriguingly, VHL protein levels were much higher in colon cancer than in adjacent
normal tissues (Fig. 7B). A representative stain is shown in Fig. 7C. We speculate that in
these colon cancer samples pVHL also retained its function, at least in regard to its ability to
target KLF4 for degradation. Because the tumor-suppressive potential of VHL is in great
part attributable to the role of its downstream-target HIF in angiogenesis, we predict that a
tumor-facilitating effect of pVHL overexpression might be a feature of early tumorigenesis
in tissues where KLF4 plays an important antimitotic role.
KLF4 turnover can affect tumor formation
To see whether KLF4 stability affects colon cancer tumorigenesis, we infected HCT116
cells with lentiviruses expressing wild type or KLF4 mutants. These cells were then tested
for colony formation in soft agar as anchorage-independent growth assays. Representative
images of stained plates as well as a quantification are shown in Fig. 7D (for raw data and
immunoblots of KLF4 levels see Supplementary Figures 7A and 7B). Wild type KLF4
greatly reduced colony formation (Fig. 7D, compare upper images and quantification), but
KLF4 with mutant ubiquitylation sites increased the inhibitory potential of KLF4 much
further (compare upper right image and lower images). While the inhibitory effect of
exogenous wild type KLF4 was around 2.5 fold, K43R and K23,43R KLF4 mutants
decreased colony formation over 10 fold. These findings confirm that KLF4 has a strong
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tumor suppressor role in colon cancer and show that the ubiquitylation sites of KLF4, and by
inference the turnover rate of KLF4, can influence tumor progression in colon cancer cells.
DISCUSSION
Previous studies have shown that pVHL plays a role in murine cell cycle control
independent of its regulation of the hypoxia inducible factors (Mack et al., 2005; Young et
al., 2008). The cyclin-dependent kinase inhibitors p21 and p27 were found to mediate
growth arrest after VHL loss in a mechanistically unidentified pathway involving Skp2 and
p400 (Fig. 7E, left side), but in a p53 (and HIF) independent fashion. The work presented
here establishes the transcription factor KLF4 as a target of the E3 ligase pVHL in murine
and human cells and provides evidence that the degradation of KLF4 by pVHL plays an
important role in VHL-dependent growth control. KLF4 was directly bound by pVHL and
studies in which pVHL was either overexpressed or depleted have documented a role of
VHL in KLF4 degradation and in determining the proliferation rate of human colorectal
cancer cells. These studies indicate that KLF4, an activator of the p21 gene, is an important
mediator of the reported VHL dependent cell cycle regulation (Fig. 7E, right side).
Parallel pathways or interconnected regulatory network?
Studies on the impact of acute pVHL loss in MEFs led to the proposal of a VHL/p400/Skp2/
p27(p21) pathway (Young et al., 2008). Our current analysis shows that pVHL, KLF4, and
p21 form a cascade also inducing cell cycle delay. But are the two pathways parallel or
interconnected? Are they cell specific? Loss of p400 has been shown to increase both p21
mRNA and protein levels and induce p21-dependent senescence in several human cell lines.
Intriguingly, p400 is a component of the human TIP60/NuA4 HAT complex. TIP60 was
found to directly interact with KLF4 and to act as co-repressor of KLF4 in the regulation of
the HDC promoter activity (Ai et al., 2007). Regarding Skp2 and p27, it was observed that
KLF4 overexpression in human pancreatic adenocarcinoma cells not only led to increased
mRNA levels of p27 and p21, but also to reduced Skp2 protein levels (Wei et al., 2008). The
mechanism and universality of Skp2 down-regulation by KLF4 are presently unknown, but
could constitute another interesting connection between players downstream of VHL (Fig.
7E).
Degradation of KLF4 and its impact on cancer
KLF4 was proposed to be a tumor suppressor based on the observation that ectopic
expression of KLF4 in several cell types results in slow growth and that KLF4 plays a role
in maintaining the integrity of the G1/S and G2/M checkpoints following DNA damage.
Several studies have shown down-regulation or mutation of KLF4 in human tumors,
especially of the colon and stomach, and over-expression of KLF4 in a human colon cancer
cell line reduces in vivo tumorigenicity (McConnell et al., 2007). Furthermore, gastric-
tissue-specific deletion of KLF4 in mice induces gastric hyperplasia and polyps (Katz et al.,
2005). This anti-proliferative activity of KLF4 is congruent with its ability to
transcriptionally activate, at least in certain cells, the cell cycle inhibitors p21, p27, and p57
and to repress various cyclins and ornithine decarboxylase (Evans and Liu, 2008).
In contrast, elevated levels of KLF4 have been reported in up to 70% of primary mammary
cancers and KLF4 over-expression at the stage of ductal carcinomas suggests that this
represents an early event in breast cancer progression. Nuclear localization of KLF4 was
found to be a prognostic factor indicating an aggressive phenotype in breast cancers.
Furthermore, depletion of KLF4 from breast cancer cells was shown to cause p53-dependent
apoptosis, in agreement with an anti-apoptotic function of KLF4 observed also in other cell
types (Rowland et al., 2005). KLF4 over-expression was also linked to the development of
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squamous cell carcinoma and unbiased genetic screens have identified KLF4 as a potential
oncogene (Rowland and Peeper, 2006). Thus, depending on the type of cancer involved,
KLF4 can play a repressive or an activating role in tumorigenesis. At present the molecular
mechanisms underlying this ambiguity are poorly understood. It was proposed that the
genetic background, particularly concerning genes controlling p21, determines the outcome
of KLF4 signaling (Rowland et al., 2005). The pathways of KLF4 and of the tumor
suppressor p53 are interlinked and both genes regulate growth arrest and apoptosis. Yet, in
contrast to p53, KLF4 seems to negatively regulate apoptosis, a fact that might at least
partially be responsible for its oncogenic potential (Rowland and Peeper, 2006). The key
role of KLF4 in this complex intersection of pro- and anti-proliferative signalling network
emphasizes the importance of understanding the factors and modifications that control
KLF4.
Von Hippel-Lindau syndrome is characterized by the dominantly inheredited predisposition
to develop highly vascularized tumors (Kaelin, 2007). Mouse models demonstrate that
homozygous disruption of VHL results in embryonic lethality and tumorigenesis in VHL
patients is associated with the loss or inactivation of the wild type allele following
Knudson’s “two-hit” hypothesis (Kaelin, 2007). Loss of VHL function is also observed in
sporadic cases of clear-cell renal carcinomas (Kaelin, 2008) and a decrease of VHL levels
has been correlated with breast cancers.
Although most studies correlate VHL function as tumor suppressor to its ability to degrade
HIF under normoxic conditions, several aspects point to a more complex role of pVHL in
tumorigenesis: Other substrates of its ubiquitin ligase activity have been identified (see
introduction) and besides the already discussed growth inhibitory effect of VHL loss on
proliferation (Mack et al., 2005; Mack et al., 2003) VHL was shown to play a role in
microtubule stability, assembly of extracellular matrix and intercellular junctions, primary
cilium maintenance (reviewed in (Nyhan et al., 2008)), spindle orientation and chromosomal
stability (Thoma et al., 2009).
Our findings that KLF4 is a high turn over protein in several human cell types and is
targeted for proteasome-dependent degradation by pVHL open the possibility to a better
understanding of HIF-independent effects of VHL functional status on tumorigenesis and
the pleiotropic phenotype of VHL mutations. While it is not yet understood how the forces
that KLF4 exerts on the balance between its ability to promote (via inhibition of apoptosis)
or inhibit (via cell cycle arrest) tumorigenesis are regulated, their effect on the cell fate
decision could be mitigated or exacerbated by pVHL levels (Fig. 7F). Thus pVHL could
conversely repress or facilitate tumor formation and, besides its well documented role as
tumor suppressor in certain tissues, play a deleterious role in other tissues given the
appropriate cellular environment. Because pVHL’s best documented tumor suppressive
action is via HIF, particularly due to the downstream regulation of VEGF-induced
angiogenesis, we envision that circumstances where pVHL promotes tumor formation is at
an early stage and in cells where KLF4 is an important inducer of cell cycle arrest after
genotoxic stress. Interestingly, it has been proposed that loss of KLF4 in colorectal cancer is
an early event (Evans and Liu, 2008) and high levels of pVHL were reported in early stages
of colorectal cancers, whereas an angiogenic switch in cancer progression was suggested to
select for downregulation of pVHL at later stages (Giles et al., 2006).
Regulation of KLF4 degradation
Although the knockdown of VHL in several cell lines led to an increase in KLF4 levels, we
do not see a strict inverse correlation between VHL and KLF4 when comparing different
cell lines (data not shown). This indicates that KLF4 degradation by VHL is tightly
regulated. Possible mechanisms include post-translational modification of KLF4 or
Gamper et al. Page 9













compartimentalization. Several substrates of ubiquitin ligases have been found to be
regulated by modification of their interaction or ubiquitylation sites. Such modifications
include phosphorylation, acetylation, or hydroxylation. The mechanisms governing KLF4
degradation by pVHL are of interest not only for the role of KLF4 in cancer, but also in
differentiation and stem cell renewal.
EXPERIMENTAL PROCEDURES
Nuclear extract preparation and complex purification from a HeLa S cell line stably
expressing KLF4
Hela S cells were infected with a retrovirus encoding FLAG-tagged KLF4. Stable tagged
KLF4 expressing cell lines were established from individual clones after selection with
puromycin. Nuclear extract from HeLa was prepared as described (Dignam et al., 1983).
KLF4 interacting proteins were purified from the nuclear extract of a HeLa cell line that
stably expresses FLAG-tagged KLF4 by immunopurification on M2 agarose (Sigma) and
washing thrice with BC buffer (10% glycerol, 20 mM Tris-HCl pH 7.9, 0.2 mM EDTA, 0.5
mM phenylmethylsulfonyl fluoride (PMSF), 1 mM DTT, 0.05% NP40) containing 300 mM
KCl and once with BC buffer containing 100 mM KCl. The complex was eluted with FLAG
peptide in BC buffer containing 100 mM KCl.
RT-PCR assays
RNA was isolated from cells with TRIZOL® (Invitrogen) and reverse transcribed with
SuperscriptTM II RT (Invitrogen) according to the manufacturer’s protocol. RTPCR results
were run on agarose gels and stained with ethidium bromide. Alternatively, cDNA was used
for quantitative PCR analysis on a StepOnePlus thermocycler (Applied Biosystems).
Interaction assays
GST-fused pVHL was expressed in the Escherichia coli strain XA90. Wild type KLF4 and
deletion mutants were labelled with 35S-methionine using TNT reticulate lysates, following
the standard protocol provided by Promega. In vitro translated proteins were incubated with
resin bound GST-pVHL (10µg) by rotating at 4°C for 4 hours in BC buffer containing 100
mM KCl and 0.1 µg/µl BSA. After washes with BC buffer containing 150 mM KCl, the
resin was directly boiled in SDS loading buffer before subjecting to SDS-PAGE. Gels were
incubated in AmplifyTM (Amersham Pharmacia) before drying and autoradiography to
enhance the signal. For in vivo interaction assays, FLAG-HA-tagged KLF4 was co-
expressed with pVHL in MDAMB231 cells. 24 h after transfection the cells were washed
and crosslinked with 1 mM dimethyl 3,3’-dithiobispropionimidate (DTBP) in PBS by
shaking for 20 minutes at room temperature. After washes with PBS, the cells were lysed in
stop-lysis-wash (SLW) buffer (50 mM Tris-HCl, pH7.5, 200 mM NaCl, 5 mM EDTA, 0.5%
NP40, 0.5 mM PMSF) and sonicated. The lysate was cleared by centrifugation and
incubated with M2 agarose for 8 h. After washes with SLW buffer, the beads were boiled in
reducing SDS buffer for elution and reversal of the crosslink. Eluates were examined by
immunoblotting. (The secondary antibodies recognize the bands of the M2 heavy and short
chains as well.)
Stability, degradation, and ubiquitylation assays
Untransfected or transiently transfected cells were treated with 100µg/ml of the protein
synthesis inhibitor cycloheximide (Sigma-Aldrich) to measure, respectively, the stability of
endogenous or exogenous levels of wild type or mutant KLF4. Unless otherwise stated, cells
were harvested 6 hours after addition of the drug. In the case of exogenous KLF4,
cycloheximide was added 2 days after transfection. The proteasome dependent degradation
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was assessed by addition of 30µM MG132 for the indicated amount of time. For VHL
dependent degradation assays HCT116 or U2OS cells were transfected with 2 µg KLF4
expression vector and either 1 or 2 µg VHL expression and/or empty vector. For
ubiquitylation assays cells were treated with 30µM MG132 for 4 hours were indicated. In
the case of experiments with tagged KLF4, cells were transfected with 10 µg FLAG-HA-
tagged KLF4 vector or empty vector. Whole cell lysates were incubated with anti-KLF4
antibody bound to Prot A/G agarose or M2 agarose for 4 h and washed thrice with BC buffer
containing 300 mM KCl and once with BC buffer containing 100 mM KCl. The beads were
boiled in reducing SDS and eluates were examined by immunoblotting against ubiquitin.
Cell culture conditions, immunohistochemical staining, cell cycle analyses, soft agar
colony formation assays, and antibodies are described in Supplementary Experimental
procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. KLF4 interacts with pVHL
(A) Short half-life of KLF4 in HeLa cells. Equal protein amounts of whole cell lysates from
HeLa cells treated for the indicated time with the protein synthesis inhibitor cycloheximide
(CHX) were probed for KLF4 by immunoblotting. (B) Proteins co-precipitating with KLF4.
Anti-FLAG (M2 agarose) immunoprecipitates from nuclear extracts of HeLa cells (control)
or HeLa cells stably transfected with a retrovirus expressing FLAG-tagged KLF4 were
peptide eluded and analyzed by SDS-PAGE with Coomassie staining. M, size marker, f:
FLAG-tag. (C) pVHL, Cullin2, and elongin B co-precipitate with KLF4. The
immunoprecipitate from the HeLa cell line that stably expresses FLAG-tagged KLF4 was
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probed for various proteins associated with ubiquitin ligase complexes. NE, nuclear extract.
(D) Interaction of in vitro translated radiolabeled KLF4 (detected by SDS-PAGE and
autoradiography) with GST-fused pVHL. (E) Co-precipitation of pVHL with FLAG-HA-
tagged KLF4 from MDAMB231 cells. Anti-FLAG (M2 agarose) immunoprecipitates (IP)
were analyzed by immunoblot with antibodies indicated on the right. Asterisks denote
signals from the light and heavy chains of M2. fh: FLAG-HA-tag.
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Figure 2. VHL regulates the turnover of KLF4
(A) Elevated KLF4 levels in Vhl negative embryonic stem cells (ESCs). Whole cell extracts
of ESCs from mice expressing pVhl (Vhl+/−) or from Vhl knockout mice (Vhl−/−)
complemented with wild type (+ wt) or mutant (+ 112H) human pVHL, were tested for
KLF4 expression by immunoblot with two different antibodies against KLF4 (1, goat
derived; 2, rabbit derived). (B) RT-PCR analysis of KLF4 and VHL (with species specific
primers) mRNAs of ESCs from mice with different VHL background. Total RNA of ESCs
was purified and cDNA was prepared. Ethidium bromide stains of PCR products are shown.
β-actin levels served as internal controls. (C) VHL-dependent half-life of KLF4. Equal
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protein amounts of whole cell lysates from Vhl knockout ESCs without (left panel) or with
reconstituted pVHL expression (right panel), treated for the indicated time with the protein
synthesis-inhibitor cycloheximide (CHX), were probed for KLF4 by immunoblot. Two
antibodies against KLF4 were used like in (A). Exposure times were adjusted to show trends
in the relative KLF4 amounts. (D) VHL knockdown leads to elevated KLF4 levels. HCT116
cells were infected with lentiviruses with an empty cassette (CON) or stably expressing
shRNA against VHL. Whole cell lysates of puromycin-selected batches or wild type
HCT116 (−) were tested for KLF4 and pVHL expression. (E) VHL mRNA levels of
HCT116 after shRNA treatment. Total RNA of infected or uninfected cells was purified and
cDNA was prepared. VHL mRNA levels were quantified by real time PCR. β-actin levels
served as internal controls. Error bars represent standard deviations.
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Figure 3. KLF4 has a high turnover rate in several cell types
(A), (B) KLF4 has a high turn over rate in HCT116 and MDAMB231. Equal protein
amounts of whole cell lysates from HCT116 (A) or MDAMB231 (B) treated for the
indicated time with the protein synthesis inhibitor cycloheximide (CHX) or the proteasome
inhibitor MG132 were probed for endogenous KLF4 by immunoblot. (C, D) Transfected
KLF4 has a high turn over rate in MDAMB231 and U2OS. MDAMB231 (C) or U2OS (D)
cells were transfected with a FLAG-HA-tagged KLF4 expression vector under the control of
a CMV promoter. Equal protein amounts of whole cell lysates from MDAMB231 or U2OS
treated for the indicated time with cycloheximide were probed for exogenous KLF4 by
immunoblot with an antibody against the hemagglutinin (HA) tag.
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Figure 4. The KLF4 amino-terminus is important for degradation and interaction with pVHL
(A) Schematic of human KLF4 with previously identified domains as well as deletion
mutants used in the present study. AD, activation domain. RD, repression domain. NLS,
nuclear localization signal. DBD, DNA-binding domain. (B) Deletion of KLF4 amino acids
1–108 stabilizes KLF4. Vectors for FLAG-HA-tagged wild type (wt) or deletion mutants of
KLF4 were transfected into U2OS. 2 days after transfection cells were mock or
cycloheximide (CHX) treated for 6 hours. Equal protein amounts of whole cell lysates were
probed for KLF4 mutant levels by immunoblot with an antibody against the hemagglutinin
(HA) tag. (C) Fine mapping of the amino-terminal KLF4 region required for degradation.
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The indicated deletion mutants were tested like in B. (D, E) An amino-terminal region of
KLF4 is required for its interaction with KLF4. Beads with GST alone or GST-fused pVHL
were incubated with various in vitro translated deletion mutants of KLF4 and bound proteins
were analyzed by SDS-PAGE plus autoradiography. Deletion of amino acids 41–50 that
stabilize KLF4 (C) does not affect pVHL binding (E).
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Figure 5. KLF4 is ubiquitylated and targeted for degradation by pVHL
(A) Dose-dependent degradation of KLF4 by pVHL. An expression vector for FLAG-HA-
tagged KLF4 was co-transfected with empty vector or increasing amounts of FLAG-HA-
tagged pVHL vector. Equal protein amounts of whole cell lysates were probed for KLF4 and
pVHL levels by immunoblot with an antibody against the hemagglutinin (HA) tag. fh:
FLAG-HA-tag. (B) An amino-terminal deletion mutant and a point mutant of KLF4 are not
degraded by pVHL. KLF4 degradation of KLF(109–470) (ΔNT) or of the KLF4 double
mutant K23R,K43R (mt) by pVHL was tested like in A. *, unspecific band. (C)
Ubiquitylation of KLF4. Endogenous KLF4 was immunoprecipitated from HCT116 and
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tested for ubiquitylation by immunoblot. Where indicated cells were treated with MG132.
(D, E) Certain point or deletion mutations affect KLF4 ubiquitylation. Cells were transiently
transfected with an expression vector for FLAG-HA-tagged wild type or KLF4 with amino-
terminal point or deletion mutations. Cells were treated with MG132 for 4 hours before
harvesting. M2 (anti-FLAG) immunoprecipitates were probed for ubiquitylated KLF4 by
immunoblot with an antibody against ubiquitin. 2% lysate input were tested as control. Δ30:
KLF4(31–470); Δ50: KLF4(51–470).
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Figure 6. Characterization of HCT116 cells with VHL knockdown
(A) p21 levels are elevated in VHL-knockdown HCT116 cells. Total RNA from HCT116
cells with wild type or knockdown levels of VHL was purified and cDNA was prepared. p21
mRNA levels were quantified by real time PCR and normalized to β-actin levels. (B) Cell
proliferation of HCT116 is impaired by VHL knockdown. Indicated numbers of cells were
plated and MTS assays were used to measure the amount of viable cells over 5 days. The
MTS values at day one were arbitrarily set at 1. (C) Reduced cell cycle entry of HCT116 by
VHL knockdown. HCT116 cells with wild type (WT) or knockdown levels of VHL (VHL
KD) were treated with BrdU for 45 minutes and stained for BrdU (upper, left panel) and
DAPI. A merged picture is shown in the lower left panel. A diagram of quantitated staining
is shown in the right panel. (D) Cell cycle profile of wild type and VHL knock down
HCT116. HCT116 cells with wild type or knockdown levels of VHL were BrdU and
propidium iodide stained and analysed by FACS. VHL knockdown leads to a strong
decrease in cells in S phase. (E) KLF4 silencing in VHL knockdown cells leads to increased
cell proliferation. HCT116 cells with knockdown levels of VHL (VHL KD) were transfected
with siRNA against KLF4 or luciferase and treated with BrdU (left panel) like in (C). Wild
type (WT) HCT116 served as comparison for the BrdU staining. (F) p21 levels are reduced
in VHL-knockdown HCT116 cells after KLF4 silencing. Total RNA from HCT116 cells
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with knockdown levels of VHL was purified after transfection with siRNA against KLF4 or
luciferase and cDNA was prepared. p21 mRNA levels were quantified by real time PCR and
normalized to β-actin levels. Error bars represent standard deviations.
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Figure 7. The role of KLF4 and VHL in colon cancer
(A) mRNA levels of VHL in colon cancer. Published Affymetrix microarray data of 5
normal and 100 cancer colon tissues were analyzed for VHL mRNA levels. None of the
analyzed cancer samples showed loss of the VHL gene or decreased VHL RNA levels. (B),
(C) Immunohistochemical analysis of KLF4 and pVHL expression in colon cancer tissues.
Sections from colon cancer and adjacent tissues were analyzed by immunostaining against
KLF4 and pVHL. Staining without primary antibody served as negative control. A
quantification of tissue staining, as described in Experimental Procedures, is shown in (B).
A representative sample is shown in (C). *, p<0.05. (D) Transformation suppression by wild
type and mutant KLF4. HCT116 cells were infected with lentiviruses expressing wild type
or KLF4 mutants and tested for colony formation in soft agar in anchorage-independent
growth assays. Wild type KLF4 greatly reduced colony formation, but KLF4 with mutant
ubiquitylation sites increased the inhibitory potential of KLF4 even further. (E) Model of
parallel pathways signaling from pVHL to p21 and p27 and possible cross talks between
them. (F) Diagram of the importance of KLF4 in cell fate decision and the regulation of
KLF4 by pVHL. Since KLF4 is thought to function as tumor suppressor or oncogene
depending on the balance between its impact on cell cycle arrest or inhibition of apoptosis,
so would its degradation by pVHL lead to either tumor promotion or suppression. Error bars
represent standard deviations.
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